• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

NIHR Oxford Health Biomedical Research Centre

MENUMENU
  • About
    • About
    • Management and core team
    • Our partners
    • Timeline of our key achievements
    • Core facilities
    • Work with us
    • Contact
  • Departments
    • NIHR Oxford Cognitive Health Clinical Research Facility
    • Brain Health Centre
    • Oxford Precision Psychiatry Lab (OxPPL)
    • Oxford Dementia and Ageing Research (OxDARE)
    • Treatment Resistant Depression Clinic
    • Experimental Medicine and Industry Partnership (EMIP)
  • Research Themes
    • Better Sleep
    • Brain Technologies
    • Data Science
    • Dementia
    • Depression Therapeutics
    • Flourishing & Wellbeing
    • Mental Health in Development
    • Molecular Targets
    • Pain
    • Preventing Multiple Morbidities
    • Psychological Treatments
  • COVID-19 Research
    • Overview
    • News
    • COVID-19 & clinical management of mental health issues
  • News & Events
    • News
    • Training and Events
    • Psychiatry Department Seminars
  • Patients & Public
    • About Patient and Public Involvement
    • Patient and Public Involvement Contacts
    • Shape our research
    • Take part in our research
    • Resources for researchers
    • Resources for the public
    • Patient and Public Involvement Strategy
    • Young people’s involvement
  • Industry
    • Collaborate with Oxford Health
    • Who Do We Work With?
    • Industry Events
    • Further Information and Additional Resources
    • Contacts for Industry
  • Training Hub
You are here: Home / News / COVID-19 research / Risk of rare blood clotting higher for COVID-19 than for vaccines

Risk of rare blood clotting higher for COVID-19 than for vaccines

19th April 2021

A new study has reported that the risk of the rare blood clotting known as cerebral venous thrombosis (CVT) following COVID-19 infection is around 100 times greater than normal, several times higher than it is post-vaccination or following influenza.

The study authors, led by Professor Paul Harrison and Dr Maxime Taquet from Oxford University’s Department of Psychiatry and the NIHR Oxford Health Biomedical Research Centre, counted the number of CVT cases diagnosed in the two weeks following diagnosis of COVID-19, or after the first dose of a vaccine. They then compared these to calculated incidences of CVT following influenza, and the background level in the general population.

They report that CVT is more common after COVID-19 than in any of the comparison groups, with 30% of these cases occurring in the under 30s. Compared to the current COVID-19 vaccines, this risk is between 8-10 times higher, and compared to the baseline, approximately 100 times higher.

The breakdown comparison for reported cases of CVT in COVID-19 patients in comparison to CVT cases in those who received a COVID-19 vaccine is:

  • In this study of over 500,000 COVID-19 patients, CVT occurred in 39 in a million patients.
  • In over 480,000 people receiving a COVID-19 mRNA vaccine (Pfizer or Moderna), CVT occurred in 4 in a million.
  • CVT has been reported to occur in about 5 in a million people after first dose of the AZ-Oxford COVID-19 vaccine.
  • Compared to the mRNA vaccines, the risk of a CVT from COVID-19 is about 10 times greater.
  • Compared to the AZ-Oxford vaccine, the risk of a CVT from COVID-19 is about 8 times greater.

However, all comparisons must be interpreted cautiously since data are still accruing. 

Paul Harrison, Professor of Psychiatry and one of the lead researchers said:

There are concerns about possible associations between vaccines, and CVT, causing governments and regulators to restrict the use of certain vaccines. Yet, one key question remained unknown: ‘What is the risk of CVT following a diagnosis of COVID-19?’. We’ve reached two important conclusions. Firstly, COVID-19 markedly increases the risk of CVT, adding to the list of blood clotting problems this infection causes. Secondly, the COVID-19 risk is higher than seen with the current vaccines, even for those under 30; something that should be taken into account when considering the balances between risks and benefits for vaccination.’

Dr Maxime Taquet, also a leading researcher on the project, said:

It’s important to note that this data should be interpreted cautiously, especially since the data on the Oxford-AstraZeneca vaccine come from European Medicines Agency monitoring, whereas the other data uses the TriNetX electronic health records network. However, the signals that COVID-19 is linked to CVT, as well as portal vein thrombosis – a clotting disorder of the liver – is clear, and one we should take note of.’

An important factor that requires further research is whether COVID-19 and vaccines lead to CVT by the same or different mechanisms. There may also be under-reporting or mis-coding of CVT in medical records, and therefore uncertainty as to the precision of the results.

To see the full data. 

Filed Under: COVID-19 research, News, Vaccination and vaccine hesitancy

Primary Sidebar

News Categories

  • News
    • Clinical Research Facility
    • COVID-19 research
      • Children, young people and family mental health
      • COVID-19 and psychiatric diagnosis
      • Online therapies and resources for clinicians
      • Patient and Public Involvement in the pandemic
      • PHOSP COVID
      • Vaccination and vaccine hesitancy
    • Research Themes
      • Better Sleep
      • Brain Technologies
      • Data Science
      • Dementia
      • Depression Therapeutics
      • Flourishing & Wellbeing
      • Mental Health in Development
      • Molecular Targets
      • Pain
      • Preventing Multiple Morbidities
      • Psychological Treatments
    • Training and Development
Tweets by OxHealthBRC
Follow @OxHealthBRC

Footer

Follow us

  • LinkedIn
  • Twitter
  • YouTube

Improving brain health: the future in mind

The National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) is a partnership between Oxford Health NHS Foundation Trust and the University of Oxford.  We are part of the Oxford Academic Health Partners.
Oxford Academic Health Partners
  • Sitemap
  • Accessibility
  • Disclaimer
  • Cookies
  • Contact

© 2023 NIHR Oxford Health Biomedical Research Centre · Log in